SRPT Sarepta Therapeutics Inc.

Sarepta Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

Sarepta Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California on Monday, January 13, 2020 at 12:30 p.m. E.T. / 9:30 a.m. P.T. Following the presentation there will be a Q&A session starting at 1:00 p.m. E.T. / 10:00 a.m. P.T.

The presentation and Q&A session will be webcast live under the investor relations section of Sarepta’s website at  and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics

Sarepta is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy (DMD) and more recently in gene therapies for limb-girdle muscular dystrophy diseases (LGMD), Charcot-Marie-Tooth (CMT), MPS IIIA and other CNS-related disorders, totaling over 20 therapies in various stages of development. The Company’s programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. Sarepta is fueled by an audacious but important mission: to profoundly improve and extend the lives of patients with rare genetic-based diseases. For more information, please visit .

Internet Posting of Information

We routinely post information that may be important to investors in the 'For Investors' section of our website at . We encourage investors and potential investors to consult our website regularly for important information about us. 

Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc.

Investors:

Ian Estepan, 617-274-4052

Media:

Tracy Sorrentino, 617-301-8566

EN
06/01/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sarepta Therapeutics Inc.

Sarepta Therapeutics Inc: 1 director

A director at Sarepta Therapeutics Inc bought 37,038 shares at 133.801USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch